| # | Drug | Count |
|---|---|---|
| 0 | PEMBROLIZUMAB | 15 |
| 1 | NIVOLUMAB | 14 |
| 2 | IPILIMUMAB | 8 |
| 3 | CARBOPLATIN | 7 |
| 4 | PEMETREXED DISODIUM | 4 |
| 5 | APIXABAN | 3 |
| 6 | ACETAMINOPHEN | 2 |
| 7 | ACETAMINOPHEN 500MG | 2 |
| 8 | ACETAMINOPHEN TABLET EXTENDED RELEASE | 2 |
| 9 | AMLODIPINE | 2 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | SODIUM HYALURONATE | 1 | 0.0012 |
| 1 | HYALURONATE SODIUM | 1 | 0.0007 |
| 2 | IPILIMUMAB | 8 | 0.0002 |
| 3 | NIVOLUMAB | 14 | 0.0001 |
| 4 | PEMBROLIZUMAB | 15 | 0.0001 |
| 5 | PEMETREXED DISODIUM | 4 | 0.0001 |
| 6 | VEMURAFENIB | 1 | 0.0001 |
| 7 | LENVATINIB | 2 | 0.0001 |
| 8 | CARBOPLATIN | 7 | 0.0001 |
| 9 | DABRAFENIB | 1 | 0.0000 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Programmed Death Receptor-1 Blocking Antibody [EPC] | 27 | 0.0003 |
| 1 | CTLA-4-directed Blocking Antibody [EPC] | 8 | 0.0002 |
| 2 | Platinum-based Drug [EPC] | 8 | 0.0000 |
| 3 | Histamine-2 Receptor Antagonist [EPC] | 2 | 0.0000 |
| 4 | Topoisomerase Inhibitor [EPC] | 1 | 0.0000 |
| 5 | Microtubule Inhibitor [EPC] | 2 | 0.0000 |
| 6 | Factor Xa Inhibitor [EPC] | 3 | 0.0000 |
| 7 | beta-Adrenergic Blocker [EPC] | 2 | 0.0000 |
| 8 | Dihydropyridine Calcium Channel Blocker [EPC] | 2 | 0.0000 |
| 9 | Kinase Inhibitor [EPC] | 3 | 0.0000 |